Stock Ratings / Health Care / ASND / financials

BBIO (29) JAZZ (47) SMMT (47) VTRS (57) ⌘ Pro Terminal →

Ascendis Pharma A/S Ordinary Share (ASND) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

$251.27 -0.68% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $250.49

Ascendis Pharma A/S Ordinary Share (ASND) carries a Roarable Rating of C+ (Hold) with 69/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.

📊 Historical Track Record: Scores of 69/100 (C+) historically posted market-perform odds over rolling 90-day windows (+2.0% avg 90D alpha vs SPY) →

ROARABLE C+ • HOLD / WATCH Cap $16.67B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on ASND Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is ASND stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-02, Ascendis Pharma A/S Ordinary Share (NASDAQ: ASND) is rated C+ (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 69/100 at a spot price of $251.27 (-0.68% 1D, market cap $16.67B). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 15/20, Executive Insider Alignment 16/20, FRED Macro Regime Fit 14/20, and SEC Balance-Sheet Forensics 12/20. Across 1016 tracked Health Care issuers, ASND ranks #90 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does ASND compare to BBIO and JAZZ in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ASND carries a Roarable C+ (69/100 RQD), trailing P/E of 32.8x, gross margin of —, and ROIC of 9.9%. By comparison, BBIO (BridgeBio Pharma Inc.) holds a E grade (29/100 RQD, P/E N/A, ROIC -35.0%, cap $13.83B) and JAZZ (Jazz Pharmaceuticals plc (Ireland)) posts a D grade (47/100 RQD, P/E N/A, ROIC -4.7%, cap $13.49B). Among the 5-stock peer group, ASND leads on earnings multiple (32.8x) while ASND leads on capital efficiency (9.9% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for ASND?

▼

For Ascendis Pharma A/S Ordinary Share (ASND), key quantitative strengths include Big institutional funds and options desks are actively positioning on the bullish side. and Clean SEC annual filing review with no major hidden accounting time-bombs., while primary risk factors center on Broader market pullbacks can still drag down strong stocks in the short run. and implied 5-year growth hurdle of 25.3%/yr. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $250.49 (-0.31%)🧬 Cannibal Buyback (-1.24% YoY Shares)⚙️ Cash Engine: 12/20 (C-) • 9.2% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 69/100 (C+) historically posted market-perform odds over rolling 90-day windows (+2.0% avg 90D alpha vs SPY • 57.3% hit rate — wait for RQD ≥ 70 breakout).

Audit Bucket Track Record →

RQD QUANT TACHOMETERHOLD / WATCH • C+

2-of-3 JEV AI Jury Bullish

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw C · Rk B

Each axis scored 0–20

12M PRICE TARGET CONE+5% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ASND)Realized 20D OHLCV Swing Band: ±5.2%

Deterministic 5-Pillar Attribution (69/100 Composite)

🔍 WHY ASND SCORES 69/100 (C+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+16/20 pts (23% of score)

Altman Z-Score 3.74 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 8/9

▲ #2 Bullish Driver: Whale & Options Positioning+15/20 pts (22% of score)

20D Institutional Volume Accumulation (±5.2% realized swing band)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution12/20 pts (-8 pt drag)

Cannibal Buyback (-1.24% YoY Shares) & executive Form 4 sales trim 8 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade C$223.21+5% Next Q

Q2 (-2Q)

Grade C+$234.33+4.9% Next Q

Q3 (-1Q)

Grade B-$245.85+2.2% Next Q

Current

Grade C+$251.27+2% Hist 90D α

Trajectory: C (61) → C+ (69)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the ASND Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 69/100 (C+) score, ASND faces multiple-compression risk if 32.8x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Broader market pullbacks can still drag down strong stocks in the short run.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Cannibal Buyback (-1.24% YoY Shares) — any gross margin slip below 49.5% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($242.32) or 200D SMA ($238.53) invalidates the momentum regime and cuts Target Base ($263.71) toward Bear Floor ($205.69).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $ASND• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “ASND Beats Next Quarter EPS Consensus (Upcoming Quarter) & Holds Above 200D SMA”

YES 69%NO 31%Trade / Inspect Odds →

VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • Trailing 12 Months

How ASND Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$368.4M (9.2% FCF Margin)

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ASND)

✓Walkthrough of ASND's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

ASND // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +9.86%⚡ TESTING RESISTANCE

2026-11-02O $249.6H $253.0L $249.6C $251.3VOL 491.5K

RES: $254.7SUP: $205.2SMA50: $242.3SMA200: $238.5

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

ASND Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 ASND Butterfly Map → + Track ASND →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

25.3%/yr Implied 5Y Growth

vs. +12.1% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on ASND today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for ASND. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for ASND today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ASND)

Health Care Rank #90 of 1016 ⚔️ BBIO vs ASND Full Matrix →

1. Head-to-Head Health Care Peer Comparison (ASND vs. BBIO, JAZZ, SMMT, VTRS)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Ascendis Pharma A/S Ordinary Share (ASND) ranks #90 by composite RQD confidence (69/100, grade C+) and #76 by equity capitalization ($16.67B). Within this direct 5-issuer industry benchmark cohort, ASND leads on earnings valuation at 32.8x trailing P/E, while ASND leads on capital efficiency and profitability with 9.9% ROIC and — gross margin. ASND currently leads its immediate peer cohort in composite quantitative strength at 69/100 (C+).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
ASND ACTIVE Ascendis Pharma A/S Ordinary Share	C+	69/100	32.8x	—	9.9%	-0.68%	$16.67B	Benchmark Subject
BBIO BridgeBio Pharma Inc.	E	29/100	—	95.8%	-35.0%	+5.97%	$13.83B	/bbio-vs-asnd →
JAZZ Jazz Pharmaceuticals plc (Ireland)	D	47/100	—	—	-4.7%	+3.92%	$13.49B	/jazz-vs-asnd →
SMMT Summit Therapeutics Inc.	D	47/100	—	—	-35.0%	-1.05%	$12.96B	/smmt-vs-asnd →
VTRS Viatris Inc.	D+	57/100	—	35.2%	-8.1%	-0.86%	$22.05B	/vtrs-vs-asnd →

2. ASND Fundamental Profitability, Capital Efficiency & Balance-Sheet Forensics

TRAILING 12M & FORWARD QUANTITATIVE SNAPSHOT

Ascendis Pharma A/S Ordinary Share (ASND) operates in Biotechnology: Pharmaceutical Preparations (Health Care) with an equity capitalization of $16.67B, trailing P/E of 32.8x, forward P/E of 27.6x, and EV/EBITDA of 21.0x. Operating profitability registers a gross margin of —, operating margin of 13.9%, net profit margin of 10.9%, ROIC of 9.9%, and free cash flow yield of 2.21%, alongside an Altman Z-Score of 3.74 and Piotroski F-Score of 8/9.

3. ASND Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is ASND stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does ASND compare to BBIO and JAZZ in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for ASND?

Where is ASND trading relative to its 50-day, 200-day, and 52-week technical levels?

ASND last traded at $251.27 (-0.68% on volume of 386,802 shares), positioning the stock +3.69% above its 50-day simple moving average ($242.32) and +5.34% above its 200-day simple moving average ($238.53). Across its 52-week range of $188.07 to $282.15, ASND sits at the 67.2% percentile with a 14-day RSI of 66.3 (BULLISH MOMENTUM) and an implied next-earnings move of ±5.2% ($238.20 to $264.34).

ASND Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

How profitable is Ascendis Pharma A/S Ordinary Share (ASND)?

In Trailing 12 Months, ASND converted $4.0B of revenue into a 52% gross margin, 13.9% operating margin, and $368.4M in free cash flow (9.2% FCF margin).

Direct Sub-Reports: ASND RQD Cockpit ASND 12M Forecast ASND Earnings & Move ASND Dividends & DRIP ASND Insiders & 13F ASND Whale Options ASND Profit Sankey ASND News & Why

ROARABLE RATING BRIEF • RQD 69/100 (C+) ✓ STAGE-C NUMBER FIREWALL VERIFIED

ASND — Ascendis Pharma A/S Ordinary Share: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T14:09:48Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, ASND scores 69 out of 100, a letter grade of C+, with the verdict "Roarable Hold — Upper Neutral / Watch for Breakout." The five pillars are:

Fundamental Cash Engine: 12 / 20. Per the Roarable RQD rating, this reflects ROIC of 9.9% and an FCF yield of 2.21%. Per the market data, the return on invested capital is modest relative to the stock's $16.67B market cap, and the free cash flow yield is low, meaning investors are paying a high price for each dollar of cash generated.
Whale / 13F Flow: 15 / 20. Per the Roarable RQD rating, this pillar reflects institutional accumulation and options positioning. The underlying holder data is not available in source data, so the pillar score cannot be traced to specific filings here.
Insider Conviction: 12 / 20. Per the Roarable RQD rating, this reflects SEC Form 4 and Congressional PTR cluster flow. The transaction-level detail is not available in source data.
Macro Regime Fit: 14 / 20. Per the Roarable RQD rating and market data, beta is 0.98, indicating the stock has moved roughly in line with the broader market. The sector-sensitivity detail is not available in source data.
Forensic Balance Sheet: 16 / 20. Per the Roarable RQD rating, Altman Z is 3.74, Piotroski F is 8/9, and Debt/Equity is 0.39. These readings describe a relatively strong balance sheet and low leverage.

What this means for a prospective investor: the strongest pillar is balance-sheet quality, while the cash-generation and insider pillars are the weakest. Per the market data, the stock trades at a trailing P/E of 32.8 and a forward P/E of 27.6, so valuation leaves limited margin for error if earnings disappoint. The 52-week range of $188.07 to $282.15 places the current price of 253 in the upper portion of that band. The C+ grade and "Upper Neutral" verdict suggest a balanced setup in which upside depends on a breakout catalyst that the source data does not identify.

Snapshot

Price	Market Cap	P/E (TTM)	Forward P/E	EV/EBITDA	EPS (TTM)	Dividend Yield	Beta	52-Wk Range	ROIC %
253	$16.67B	32.8	27.6	21	7.7	0%	0.98	$188.07 - $282.15	9.9%

Business

Ascendis Pharma A/S Ordinary Share (ASND) is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry, per the profile. Per the market data, operating margin is 13.9% and net margin is 10.9%. Specific products, customers, and revenue model are not available in source data.

Open Questions

What are the company's specific revenue sources, products, and customers, given that the source data gives only sector and industry labels?
What period-level revenue, net income, cash, and debt figures support the reported margins and ratios?
What institutional, insider, and Congressional transactions drive the Whale and Insider pillar scores?
What catalyst is expected to produce the "breakout" referenced in the verdict?
Why is gross margin reported as 0% and what is the basis for the Roarable RQD sub-scores?

ASND Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Ascendis Pharma A/S Ordinary Share (ASND) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to ASND Debate Forum (3) ↓

🟡 MARKET WIRE Yahoo • 7d ago

TransCon® PTH (Palopegteriparatide) Demonstrates Sustained, Clinically Meaningful Improvements in Kidney Function in Adults with Hypoparathyroidism Treated Up to 5 Years

COPENHAGEN, Denmark, Oct. 26, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced new data demonstrating early, sustained, and clinically meaningful improvements in kidney function in adults with

Read Full Source ↗

🟡 MARKET WIRE Benzinga • 7d ago

Ascendis Pharma Reports Sustained Kidney Function Improvements Over 5-Years With TransCon PTH In Adults With Hypoparathyroidism

Ascendis Pharma A/S (NASDAQ:ASND) today announced new data demonstrating early, sustained, and clinically meaningful improvements in kidney function in adults with hypoparathyroidism treated with TransCon® PTH

Read Full Source ↗

🟡 MARKET WIRE Yahoo • 12d ago

Bet on This New GLP-1 ETF to Gain Exposure to a Booming Market

GLP-1 drugs are fueling a booming peptide market. Can the new PEPT ETF capitalize on rising demand and expanding medical applications?

Read Full Source ↗

🟢 CATALYST Yahoo • 13d ago

RBC Capital names top healthcare stocks as sector upgraded to overweight

Investing.com -- RBC Capital has upgraded the Healthcare sector to Overweight from Market Weight, identifying 11 high-conviction stock ideas across therapeutics and non-therapeutics segments. The upgrade is supported by

Read Full Source ↗

🟡 MARKET WIRE Yahoo • 17d ago

ASND Shares Shrug Off Positive European Opinion For FDA-Approved Achondroplasia Drug

Ascendis said the Committee for Medicinal Products for Human Use adopted a positive opinion on Ascendis’s application seeking approval for the drug in achondroplasia.

Read Full Source ↗

🔴 RISK WATCH Yahoo • 17d ago

Ascendis Pharma's TransCon CNP Gets Positive EU Recommendation for Children With Achondroplasia

Ascendis Pharma (ASND) said Friday that the European Medicines Agency's Committee for Medicinal Prod

Read Full Source ↗

🔴 RISK WATCH Yahoo • 17d ago

Once-Weekly TransCon® CNP (Navepegritide) Receives Positive CHMP Opinion for the Treatment of Achondroplasia in Children

Final European Commission decision expected during Q4 2026COPENHAGEN, Denmark, Oct. 16, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the Committee for Medicinal Products for Human Use

Read Full Source ↗

🔴 RISK WATCH Benzinga • 17d ago

Ascendis Pharma Receives Positive Opinion From Committee For Medicinal Products For Human Use Of European Medicines Agency For Marketing Authorization Of TransCon CNP In EU To Treat Achondroplasia

Ascendis Pharma A/S (NASDAQ:ASND) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending marketing authorization

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

ASND Bull vs. Bear Conversation Board — What's Your Call at $251.27?

🐂 50% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON ASND 🐻 50% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk ⚖️ DEBATE HOST 🎯 Target: $273.24 (+8.0%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is ASND (C+ • RQD 69/100) a Buy at $253.00?

Welcome to the ASND (Ascendis Pharma A/S Ordinary Share) Roar Pit. Current RQD Composite is 69/100 (Roarable Hold — Upper Neutral / Watch for Breakout) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on valuation multiple compression (32.8x trailing P/E). Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

BE BearTrap_Alert Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $197.34 (-22.0%)

Spot @ $253.00

Pump the brakes on ASND — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on ASND, but look at what you are paying: 32.8x trailing P/E with tightening sector spreads. Unless Ascendis Pharma A/S Ordinary Share expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

SI SiliconVal_Bull Verified K Arena Trader 🐂 BULLISH 🎯 Target: $303.60 (+20.0%)

Spot @ $253.00

ASND cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on ASND, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $253.00 (52-wk range $188.07 - $282.15), any beat on forward guidance forces shorts and underweight funds to chase.